- Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates
- Sana Biotechnology to Present at May and June 2024 Investor Conferences
- Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
- Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
- Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
- Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Sana Biotechnology Announces Pricing of Upsized Public Offering
- Sana Biotechnology Announces Proposed Public Offering of Common Stock
- Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
- Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
More ▼
Key statistics
On Thursday, Sana Biotechnology Inc (SANA:NSQ) closed at 9.27, -22.75% below its 52-week high of 12.00, set on Mar 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.34 |
---|---|
High | 9.49 |
Low | 8.54 |
Bid | 8.33 |
Offer | 11.50 |
Previous close | 8.55 |
Average volume | 2.34m |
---|---|
Shares outstanding | 221.50m |
Free float | 202.38m |
P/E (TTM) | -- |
Market cap | 1.89bn USD |
EPS (TTM) | -1.53 USD |
Data delayed at least 15 minutes, as of May 16 2024 21:15 BST.
More ▼